We operate Jiarun Hospital and its two branch hospitals, collectively being a private hospital with 950 beds located in Harbin, the capital of Heilongjiang Province in northeastern China. Jiarun Hospital offers patients care and pharmaceuticals in the areas of both Western and Chinese medical practices. Jiarun specializes in Pediatrics, Dermatology, Ears, Nose and Throat (ENT), Traditional Chinese Medicine (TCM), Ophthalmology, Internal Medicine, Dentistry, General Surgery, Rehabilitation Science, Gynecology, General Medical Services, etc. Our ambulances operate 24 hours a day.
Company profile
Ticker
JRSS
Exchange
Website
CEO
Li Hua Sun
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
JRSIS Health Care Limited • Runteng Medical Group Company Limited • Harbin Jiarun Hospital Co., Ltd. • Harbin Jiarun Hospital Co., Ltd. ...
JRSS stock data
Latest filings (excl ownership)
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Sep 22
NT 10-Q
Notice of late quarterly filing
12 Aug 22
8-K
Entry into a Material Definitive Agreement
9 Jun 22
10-Q
2022 Q1
Quarterly report
20 May 22
NT 10-Q
Notice of late quarterly filing
16 May 22
10-K
2021 FY
Annual report
15 Apr 22
NT 10-K
Notice of late annual filing
31 Mar 22
8-K
Other Events
23 Nov 21
10-Q
2021 Q3
Quarterly report
15 Nov 21
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 11.08 k | 11.08 k | 11.08 k | 11.08 k | 11.08 k | 11.08 k |
| Cash burn (monthly) | 8.86 k | 43.05 k | 44.15 k | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 34.63 k | 168.28 k | 172.61 k | n/a | n/a | n/a |
| Cash remaining | -23.55 k | -157.20 k | -161.53 k | n/a | n/a | n/a |
| Runway (months of cash) | -2.7 | -3.7 | -3.7 | n/a | n/a | n/a |
Institutional ownership, Q1 2022
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 0.00 |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|